Lack of BRAF mutations in hyalinizing trabecular neoplasm by Baloch, Zubair W et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
CytoJournal
Open Access Case Report
Lack of BRAF mutations in hyalinizing trabecular neoplasm
Zubair W Baloch*†1, Kanchan Puttaswamy†3, Marcia Brose†2,3 and 
Virginia A LiVolsi†1,3
Address: 1Departments of Pathology and Laboratory Medicine, 3400 Spruce Street, University of Pennsylvania Medical Center, Philadelphia, PA, 
19104, USA, 2Department of Hematology & Oncology, 3400 Spruce Street, University of Pennsylvania Medical Center, Philadelphia, PA, 19104, 
USA and 3Department of Otorhinolaryngology, 3400 Spruce Street, University of Pennsylvania Medical Center, Philadelphia, PA, 19104, USA
Email: Zubair W Baloch* - baloch@mail.med.upenn.edu; Kanchan Puttaswamy - Kanchan@mail.med.upenn.edu; 
Marcia Brose - BroseM@mail.med.upenn.edu; Virginia A LiVolsi - linus@mail.med.upenn.edu
* Corresponding author    †Equal contributors
Abstract
The hyalinizing trabecular neoplasm (HTN) of the thyroid is an unusual and controversial lesion.
Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear
features and presence of psammoma bodies. Others consider it an adenoma. Molecular studies
have found RET/PTC translocations in some examples, supporting HTN as a PTC; however
mutations in BRAF (another marker for PTC) have not been found.
We report two cases of classic HTN and a case of trabecular PTC and show BRAF mutations in
the latter and not in HTN. Trabecular growth pattern is insufficient for a diagnosis of HTN and
lesions with such a pattern and nuclear features of PTC are cancers. Morphologically classic HTN
are not associated with metastatic potential and should be considered adenomas.
Background
The hyalinizing trabecular neoplasm (HTN) is a follicular
derived lesion that has a distinctive histology. It was first
described by Carney and colleagues in 1987 as an unusual
tumor of thyroid with benign clinical behavior.[1] Micro-
scopically, these tumors are encapsulated (usually thin
capsule) and grow in nests that are surrounded by dense
hyaline stroma.[1,2] The histology is reminiscent to that
seen in paragangliomas; however, the tumor is derived
from the follicular epithelium.[3] The nuclear features of
the tumor cells are similar to those seen in papillary thy-
roid carcinoma (PTC) i.e. elongated nuclei with chroma-
tin clearing, intranuclear grooves and inclusions.[1,4-7]
Psammoma bodies have also been reported in HTN.[1]
Since its description some experts believe that HTN is an
encapsulated variant of PTC based upon its nuclear cytol-
ogy, immunoprofile and RET-oncogene rearrangements
while other believe that this is not a distinct entity because
similar growth pattern can be encountered in other pri-
mary and secondary tumors of the thyroid. [7-14]
By immunohistochemistry, the cells of hyalinizing trabec-
ular neoplasm stain positive for thyroglobulin, cytokera-
tin-19 and negative for calcitonin, HBME-1 and galectin-
3 although the presence of other neuroendocrine markers
has been described[10,15]
RET oncogene encodes the tyrosine kinase (TK) mem-
brane receptor for glial cell line-derived neuron-trophic
factors. In PTC chromosomal translocations at 10q11.2
lead to the fusion of the RET TK domain to heterologous
genes (RET/PTC oncogenes) and causing activation of its
signaling and transforming properties. RET/PTC1 and
RET/PTC3 are the most common translocations seen in
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cases of PTC. RET/PTC translocations have been described
in some cases of HTN[11]
The somatic mutations of BRAF gene leading to the substi-
tution of a valine for a glutamic acid (V600E) have been
found in 36–69% of PTC and are independent of RET/
PTC translocations and RAS gene mutations. To date
BRAF mutations have not been detected in HTN. [16-20]
In the present study we report pathologic features and
BRAF mutation analysis in 2 cases of HTN and 1 case of
trabecular variant of PTC.
Material and methods
Archival paraffin-embedded tumor samples were
retrieved from the pathology files at the University of
Pennsylvania Medical Center (2 cases of HTN) and per-
sonal consultation files of one of the authors (VAL, 1
case). In all cases hematoxylin and eosin stained slides
were available; in one case of HTN fine-needle aspiration
slides were also available for review.
DNA isolation and sequencing
From paraffin slides, five 10 micron thick sections were
macro dissected for DNA extraction using Qiagen DNA
Mini Kit protocol (Hilden, Germany). The BRAF exon 15
was amplified from genomic DNA obtained from the par-
affin samples by polymerase chain reaction (PCR) with
the following primers: BRAFex15Forward
5'TCATAATGCTTGCTCTGATAGGA3'  and
BRAFex15Reverse 5'GGCCAAAAATTTAATCAGTGGA3'.
PCR was performed using the following amplification
conditions: initial denaturation at 95°C for 15 min fol-
lowed by 35 cycles of the following steps: denaturation at
95°C for 30 s, annealing at 56.4°C for 30 s, and elonga-
tion at 72°C for 30 s. After the last cycle, a final extension
at 70°C for 10 minutes was performed. The amplified
products were electrophoresed on a 1.2% gel at 110 V for
1.5 hours and the BRAF bands (~220 bp) were cut using
sterile blade and purified using Qiagen Gel Extraction Kit
(Hilden, Germany). The samples were analyzed on an ABI
PRISM 3730 Sequence Analyzer (Applied Biosystems, Fos-
ter City, CA, USA). BRAF V600E mutations were con-
firmed by reamplification by polymerase chain reaction
and by sequencing from both 5' and 3' ends. Pooled
genomic DNA (showing wild type BRAF sequence)




All three patients were females and the average age was 50
yrs. The tumor size in HTN cases was 1.2 and 1.5 cm and
papillary carcinoma 2.0 cm.
In one case of HTN fine-needle aspiration (FNA) was per-
formed under ultrasound guidance. The FNA slides
showed elongated tumor cells with nuclear features of
papillary carcinoma embedded in an acellular stroma.
[Fig 1A] The surgical pathology slides of both cases of
HTN showed classic histologic features as described by
Carney et al.[1] [Fig 2]
The case of trabecular variant of papillary carcinoma was
comprised of a thinly encapsulated circumscribed tumor
showing tumor cells with nuclear features of PTC arranged
in trabeculae with minimal sclerosis. There was no evi-
dence of capsular or vascular invasion and the tumor was
confined to the thyroid. [Fig 3]
BRAF mutations
BRAF exon 15 was PCR-amplified and subjected to direct
sequencing of genomic DNA from all three cases. No
BRAF mutations were detected in HTN [Fig. 4]; a hetero-
zygous V600E mutation was found in the case of PTC with
trabecular growth pattern [Fig 5].
Discussion
The debate over whether HTN is a benign tumor or a var-
iant of PTC is ongoing.[7,13] Most experts consider this
tumor to be benign based on that all cases of HTN which
show classic morphology as described by Carney et al fail
to show unequivocal capsular and/or vascular invasion
and have not metastasized.[7] However, one cannot
totally deny that this is not a variant of PTC due to nuclear
cytology, immunoprofile and presence of RET/PTC trans-
Cytology of HTN Figure 1
Cytology of HTN. Papanicolaou stained fine-needle aspira-
tion of hyalinizing trabecular neoplasm showing elongated 
tumor enveloped by or associated with acellular stroma. The 
tumor cells demonstrate nuclear features of papillary carci-
noma (arrow and inset).CytoJournal 2006, 3:17 http://www.cytojournal.com/content/3/1/17
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locations[10,11,21] In addition, some authors have also
suggested that this term should not be used specifically to
describe a tumor of thyroid because similar growth pat-
tern can be seen in cases of follicular adenoma, papillary
carcinoma and metastatic neuroendocrine tumors to the
thyroid gland.[8,14] Because of this debate most experts
designate these tumors as hyalinizing trabecular neo-
plasm.[7,22]
Mitogen Activated Protein Kinase (MAPK) signaling cas-
cades are highly conserved signal transduction pathways
that facilitate communication between a cell and its extra-
cellular environment. They coordinate the regulation of a
diverse array of gene products, whose expression in turn
directs key cellular functions including pathways central
to embryogenesis, cell differentiation, proliferation, and
death, as well as a number of homeostatic responses of
terminally differentiated cells. The Ras-Raf-MEK-ERK
MAPK pathway is a particularly well studied MAPK path-
way unique to metazoans and consists of a three-tiered
kinase cascade from Raf-to-ERK. While activating muta-
tions in the RAS gene family have long been accepted as
early events in this process [16], mutations in the B-RAF
gene have only recently been recognized for their impor-
tant contribution to tumor progression Primary malig-
nant melanomas harbor B-RAF mutations at a frequency
of 60–67%, while colorectal cancers are affected in
approximately 10–12% of all cases sampled. BRAF muta-
tion in PTC can range from 29–83% and exclusively occur
as the T1799A transversion mutation in exon 15; the
mutations in exon 11 (seen in non-thyroidal tumors) are
not seen in thyroid tumors.[17,18,23]
In this report we show that cases of HTN which demon-
strate classic morphology as described by Carney et al do
not demonstrate BRAF  mutations. The trabecular PTC
BRAF analysis Figure 5
BRAF analysis. Sequence chromatogram of trabecular vari-
ant of papillary thyroid carcinoma- with BRAF exon 15 for-
ward primer shows BRAF mutation.
Histology of HTN Figure 3
Histology of HTN. Trabecular variant of papillary thyroid 
carcinoma showing trabecular/paraganglioma-like growth 
pattern.
Cytology of HTN Figure 2
Cytology of HTN. Hyalinizing trabecular neoplasm display-
ing circumscription, encapsulation, tumor cells arranged in 
nests with intervening hyalinized stroma. The tumor cells 
demonstrate nuclear features of papillary carcinoma (inset).
BRAF analysis Figure 4
BRAF analysis. Sequence chromatogram of hyalinizing 
trabecular neoplasm with BRAF exon 15 forward primer 
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case showed BRAF mutation (heterozygous V600E muta-
tion). As mentioned-above trabecular growth pattern can
occur in other thyroid tumors such as papillary thyroid
carcinoma, however, in our experience these cases lack the
distinct hyalinized stroma enveloping individual tumor
cells as seen in HTN. Based on our and other studies
[17,24] which have shown absence of BRAF mutations in
HTN one can assume that this tumor is not a variant of
PTC. However, the caution has to be exercised in confirm-
ing the benign nature of this tumor on the basis of
absence of BRAF mutation. Since other molecular markers
such as RET/PTC and Galectin-3 which were initially
thought to be only expressed in PTC are now seen in some
benign lesions of the thyroid.[25] Therefore, at present it
is advisable to diagnose these tumors as HTN and relay to
clinicians that this tumor behaves in benign fashion.
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